ClinicalTrials.gg
TerminatedNCT03552549Updated Jul 24, 2019Results posted

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

A Phase 2/3 interventional study of PEG-Intron and INTRON A in Melanoma, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-07-24.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment

Why this study was terminated
This study was closed to enrollment prematurely due to sub-optimal accrual.

From the registry’s dates

  • Registered 19 years 9 months after the study started (first participant enrolled Aug 1998, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing peginterferon alfa-2b in Melanoma — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Melanoma.

Enrollment
4th of 14
126 · median 36
Started
1998
the only one that year
Phase 2/3
Only one
of the 14
Registered
14th of 14
by date
Lead sponsor
5 of 14
Merck Sharp & Dohme LLC

Among the 14 studies testing peginterferon alfa-2b in Melanoma, this one is the 4th largest by enrollment, is the only one that started in 1998, is the only one in phase 2/3, and was the 14th registered.

Melanoma

3,372 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 14 studies testing peginterferon alfa-2b in Melanoma is open now. The open studies under Melanoma, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing peginterferon alfa-2b in Melanoma as a file.
02

Study summary

This is a Phase II/III randomized, controlled, multicenter, open-label study designed to assess the safety, efficacy, and impact on quality of life of PEG Intron (MK-4031) and INTRON® A (MK-2958) and the pharmacokinetics of PEG Intron when given as adjuvant (after surgery) therapy in participants with resected (surgically removed) Stage III node-positive cutaneous melanoma.

Read the detailed description

This study was closed to enrollment prematurely due to sub-optimal accrual. Participants who were enrolled prior to enrollment closure were allowed to continue to receive study drug; these participants were followed for safety only.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have documented primary cutaneous melanoma meeting one of the following staging criteria:

    • Primary melanoma of any stage in the presence of N1 regional lymph node detected at elective lymph node dissection or sentinel node , with clinically inapparent regional lymph node metastasis (any pTN1M0).
    • Clinically apparent N1 or N2a regional lymph node involvement synchronous with primary melanoma of T1-4 (any pTN1-2aM0).
    • Regional lymph node recurrence at any interval after appropriate surgery for primary melanoma of any depth (any primary tumor [pT], r N1-2a M0).
  • Participants must have had all known disease completely resected with adequate surgical margins within 56 days prior to randomization into the study
  • Participants must have an (ECOG) performance status of 0 or 1
  • Participants must have adequate hepatic, renal and bone marrow function as defined by the following parameters obtained within 14 days prior to initiation of study treatment:

    • Hematology: white blood cells (WBC) ≥3,000 cells/µL and ≥9 g/dL.
    • Renal and hepatic function: serum creatinine \<2.0 mg/dL; (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \<2 times upper limit of laboratory normal (); and serum \<2 times ULN
  • Participants must sign and date a voluntary form before study entry, be willing to participate in this study and agree to complete all follow-up assessments.

Exclusion criteria

Exclusion Criteria:

  • Participants who have received any prior chemotherapy, immunotherapy hormonal or radiation therapy for melanoma.
  • Participants who have evidence of distant or non-regional lymph node , in-transit metastases, or positive lymph nodes with an unknown primary.
  • Participants whose disease cannot be completely surgically resected because of gross extracapsular extension.
  • Participants who have previously received interferon for any reason.
  • Participants who have severe cardiovascular disease, i.e., arrhythmias requiring chronic treatment, congestive heart failure ( [NYHA] Class III or IV) or symptomatic ischemic heart disease.
  • Participants who have a history of neuropsychiatric disorder requiring hospitalization.
  • Participants with thyroid dysfunction not responsive to therapy.
  • Participants with uncontrolled diabetes mellitus.
  • Participants with a history of prior within the past 5 years other than surgically cured non-melanoma skin cancer or cervical carcinoma in situ.
  • Participants who have a history of seropositivity for (HIV).
  • Participants who are pregnant, lactating, or of and not practicing an effective means of .
  • Participants with active and/or uncontrolled infection, including active hepatitis.
  • Participants with a medical condition requiring chronic systemic .
  • Participants who are known to be actively abusing alcohol or drugs.
  • Participants who have received any experimental therapy within 30 days prior to randomization in this study.
  • Participants who have not recovered from the effects of recent surgery.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    PEG-Intron

    Participants with stage III node positive cutaneous melanoma will receive subcutaneous PEG-Intron (6.0 ug/kg weekly) for 2 years post-surgery.

    Biological: PEG-Intron

  • Experimental
    INTRON A

    Participants with stage III node positive cutaneous melanoma will receive intravenous INTRON A (20 million international units \[MIU\]/m\^2/day, 5 days a week) for 4 weeks followed by subcutaneous INTRON A (10 MIU/m\^2 three times per week) for 48 weeks post-surgery.

    Biological: INTRON A

Interventions

  • BiologicalPEG-Intron

    Polyethylene glycol (PEG)12000 Interferon alfa 2-b subcutaneous injection.

    Also known as: peginterferon alfa-2b, SCH 54031, MK-4031

  • BiologicalINTRON A

    Interferon alfa-2b, recombinant for intravenous injection.

    Also known as: interferon alfa-2b, SCH 30500, MK-2958

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Progression-free survival time was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause. PFS was to be assessed by clinical observation, with recurrence documented by appropriate radiographic and histologic methods, and confirmed by Independent Central Review.

    Time frame: From time of randomization to time of progression or death (up to approximately 26 months)

Secondary outcomes

  1. Overall Survival

    Overall survival (OS) is the time from randomization to death due to any cause. Participants were to be followed for survival every 3 months. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. After the early termination of the study, participants were followed for safety only. Although the OS analysis is not in the clinical study report due to early termination of the study, an OS ad hoc analysis was requested by the FDA and is therefore presented in this outcome measure. Below table presents the median duration of survival for participants.

    Time frame: From time of randomization to time of death (up to approximately 26 months)

07

Results

Posted Jul 24, 2019
Limitations and caveats
The study was closed to enrollment prematurely due to sub-optimal accrual. Adverse event preferred terms were converted from WHO-ART dictionary to the MedDRA version 10.0.

Participant flow

Participant flow — Overall Study
MilestonePEG-IntronINTRON A
Started6363
Treated6262
Completed1011
Not completed5352
Withdrew: Disease progression2517
Withdrew: Adverse event in first 12 months128
Withdrew: Withdrawal by subject77
Withdrew: Unknown (no reason provided)42
Withdrew: Not in participant's best interest21
Withdrew: Did not complete study treatment23
Withdrew: Did not meet eligibility criteria10
Withdrew: Administrative014

Outcome measures

PrimaryProgression-free Survival (PFS)

Progression-free survival time was defined as the time from the date of randomization to the date of disease progression or the date of death regardless of the cause. PFS was to be assessed by clinical observation, with recurrence documented by appropriate radiographic and histologic methods, and confirmed by Independent Central Review.

Time frame:
From time of randomization to time of progression or death (up to approximately 26 months)

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival (OS) is the time from randomization to death due to any cause. Participants were to be followed for survival every 3 months. Participants without documented death at the time of the final analysis were to be censored at the date of the last follow-up. After the early termination of the study, participants were followed for safety only. Although the OS analysis is not in the clinical study report due to early termination of the study, an OS ad hoc analysis was requested by the FDA and is therefore presented in this outcome measure. Below table presents the median duration of survival for participants.

Time frame:
From time of randomization to time of death (up to approximately 26 months)
Reported as:
Median · Months
Overall Survival
MonthsPEG-IntronINTRON A
Overall SurvivalNA (25.63 to NA)23.72 (20.67 to NA)
Statistical analysis
  • PEG-Intron vs INTRON A · Hazard ratio (hr): 0.71 · 95% CI 0.28 to 1.77Hazard ratio presented as PEG-Intron/INTRON A; HR \<1 indicates treatment effect in favor of PEG-Intron.

Adverse events

Collected over Up to approximately 26 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PEG-Intron11/63 (17.5%)24/63 (38.1%)61/63 (96.8%)
INTRON A9/63 (14.3%)19/63 (30.2%)60/63 (95.2%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventPEG-IntronINTRON A
HEPATIC ENZYME INCREASEDInvestigations2/634/63
LYMPHADENOPATHYBlood and lymphatic system disorders3/631/63
VERTIGOEar and labyrinth disorders0/632/63
NAUSEAGastrointestinal disorders2/630/63
VOMITINGGastrointestinal disorders2/632/63
INJECTION SITE NECROSISGeneral disorders2/630/63
PYREXIAGeneral disorders0/632/63
ALANINE AMINOTRANSFERASE INCREASEDInvestigations2/631/63
NEUTROPENIABlood and lymphatic system disorders1/631/63
THROMBOCYTOPENIABlood and lymphatic system disorders1/630/63
Most frequent other events
Showing 10 of 61
Most frequent other events
EventPEG-IntronINTRON A
HEADACHENervous system disorders39/6333/63
PYREXIAGeneral disorders36/6330/63
CHILLSGeneral disorders24/6332/63
NAUSEAGastrointestinal disorders29/6327/63
FATIGUEGeneral disorders26/6328/63
MYALGIAMusculoskeletal and connective tissue disorders28/6328/63
ANOREXIAMetabolism and nutrition disorders23/6315/63
ASTHENIAGeneral disorders22/6315/63
DIARRHOEAGastrointestinal disorders21/6315/63
VOMITINGGastrointestinal disorders20/6313/63

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PEG-IntronINTRON ATotal
Mean48.1 ± 13.649.2 ± 12.248.6 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)PEG-IntronINTRON ATotal
Female242246
Male394180
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 1998 to primary completion in Feb 2001, 30 months.

Results were first posted in Jul 2019, 18 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2018
First posted
Jun 12, 2018
StartActual
Aug 5, 1998
Primary completionActual
Feb 19, 2001
CompletionActual
Feb 19, 2001
Results first posted
Jul 24, 2019
Last update
Jul 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03552549
Responsible party
Sponsor
First posted
Jun 12, 2018
Start date
Aug 5, 1998
Primary completion
Feb 19, 2001
Completion
Feb 19, 2001
Results posted
Jul 24, 2019
Last update
Jul 24, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Interferon alpha-2

Start the discussion